Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1895344, SBRT, and Pembrolizumab in Recurrent HNSCC
NCT04576091Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elimusertib in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Primary endpoints: Maximum-tolerated Dose at 6 weeks, Incidence of Dose Limiting Toxicities at 90 days and 2 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
elimusertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04576091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576091.